What are the contraindications, dosing regimen, and monitoring considerations for initiating flecainide therapy?

Considerations When Administering Flecainide

Flecainide should only be used in patients without structural heart disease, coronary artery disease, or left ventricular dysfunction (LVEF <40%), and must be combined with AV nodal blocking agents to prevent rapid ventricular rates during atrial flutter. 1

Absolute Contraindications

Flecainide is contraindicated in the following patients 2, 1, 3:

• Structural heart disease: Coronary artery disease, history of myocardial infarction, or active ischemia
• Left ventricular systolic dysfunction: LVEF <40%
• Significant left ventricular hypertrophy
• Advanced conduction system disease:
  • Second- or third-degree AV block without pacemaker
  • Left bundle branch block
  • Right bundle branch block with left hemiblock (bifascicular block)
• Severe renal impairment: Creatinine clearance <35 mL/min
• Severe hepatic impairment
• Cardiogenic shock
• Known hypersensitivity to flecainide

Pre-Initiation Assessment

Before starting flecainide, perform the following 1:

1. Baseline ECG: Document PR interval, QRS duration, and QTc
2. Cardiac imaging: Echocardiogram to assess LVEF and exclude structural heart disease
3. Ischemia assessment: For patients >50 years or with atherosclerotic risk factors, consider stress testing to exclude coronary artery disease
4. Renal function: Calculate creatinine clearance
5. Hepatic function: Assess liver enzymes

Dosing Regimen

Standard Dosing 2, 3

• Paroxysmal supraventricular arrhythmias/atrial fibrillation:

  • Start: 50 mg twice daily
  • Titrate: Increase by 50 mg twice daily every 4 days as needed
  • Maximum: 300 mg/day

• Sustained ventricular tachycardia:

  • Start: 100 mg twice daily
  • Titrate: Increase by 50 mg twice daily every 4 days
  • Maximum: 400 mg/day (though most patients respond to ≤300 mg/day)

Special Populations 3

• Renal impairment (CrCl <35 mL/min): Start 100 mg once daily; requires plasma level monitoring
• Moderate renal impairment: Start 100 mg twice daily; consider plasma level monitoring
• Concurrent amiodarone: Reduce flecainide dose by 50% and monitor closely

Critical timing consideration: Steady-state plasma levels require 3-5 days at a given dose due to flecainide's 12-27 hour half-life. Never increase doses more frequently than every 4 days. 3

Mandatory Concomitant Therapy

Always prescribe an AV nodal blocking agent (beta-blocker or non-dihydropyridine calcium channel blocker) with flecainide to prevent 1:1 AV conduction if atrial fibrillation converts to atrial flutter with rapid ventricular response. 1, 2

Monitoring Requirements

ECG Monitoring 2, 1, 2

• Baseline ECG: Before initiation
• Follow-up ECG: 48-72 hours after starting or after any dose increase
• Critical threshold: Discontinue or reduce dose if QRS duration increases >25% from baseline (indicates proarrhythmia risk)
• Monitor PR interval prolongation

Plasma Level Monitoring 3

Strongly recommended in:

• Severe renal or hepatic impairment (mandatory)
• Concurrent amiodarone therapy (mandatory)
• Heart failure patients
• Moderate renal disease

Therapeutic range: 0.2-1.0 mcg/mL (200-1,000 ng/mL)
Risk increases: Trough levels >1.0 mcg/mL associated with increased adverse cardiac events

Ongoing Monitoring 1

• Annual assessment: Evaluate for symptoms of coronary artery disease in patients on long-term therapy
• Stress testing: Perform if new cardiac symptoms develop
• Renal function: Monitor periodically, especially in elderly patients

Common Pitfalls and Caveats

1. Proarrhythmia risk: The CAST trial demonstrated increased mortality with flecainide in post-MI patients with ventricular ectopy—this finding applies specifically to patients with structural heart disease and ischemia, not to appropriately selected AF patients without these conditions. 2

2. Atrial flutter with rapid conduction: Flecainide can organize atrial fibrillation into atrial flutter, which may conduct 1:1 to the ventricles causing dangerous tachycardia—this is why AV nodal blockade is mandatory. 1, 2

3. Negative inotropic effects: Even in patients without baseline LV dysfunction, flecainide can precipitate heart failure, particularly at higher doses or in the setting of cardioversion. 4

4. Drug interactions: Flecainide levels increase significantly with amiodarone, requiring 50% dose reduction. 3

5. Renal elimination: Flecainide is primarily renally cleared; half-life can extend dramatically in renal impairment (reported up to 56.8 hours vs. labeled 11 hours). 5

6. Narrow therapeutic index: Small dose changes can produce disproportionate plasma level increases, particularly in children and patients with renal impairment. 3, 6

Initiation Setting

• Sustained ventricular tachycardia: Initiate in-hospital with rhythm monitoring 3
• Paroxysmal supraventricular arrhythmias/AF: May initiate outpatient in carefully selected patients without structural heart disease 2, 7

Toxicity Recognition

Signs of flecainide toxicity include 8:

• Wide QRS complex (>25% increase from baseline)
• Accelerated idioventricular rhythm
• Bradyarrhythmias
• Hypotension/cardiogenic shock
• Ventricular tachycardia/fibrillation

Management: Discontinue flecainide immediately; consider sodium bicarbonate for wide-complex tachycardia associated with toxicity. 8